Publications by authors named "Moshe Levy"

Claim this Profile
A
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Sheri Skerget, Daniel Penaherrera, Ajai Chari, Sundar Jagannath, David S Siegel, Moshe Levy

Nat Genet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.
Barry Paul, Jiri Minarik, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Moshe Levy

EJHaem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III SIERRA Trial of I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow, Moshe Y Levy

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.
Ehab L Atallah, Michael J Mauro, Koji Sasaki, Moshe Y Levy, Paul Koller

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Sheri Skerget, Daniel Penaherrera, Ajai Chari, Sundar Jagannath, David S Siegel, Moshe Levy

Nat Genet· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter

Haematologica· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An extended bore length solid-state digital-BGO PET/CT system: design, preliminary experience, and performance characteristics.
John A Kennedy, Tala Palchan-Hazan, Quentin Maronnier, Olivier Caselles, Frédéric Courbon, Moshe Levy

Eur J Nucl Med Mol Imaging· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, Laura Morrison, Frederic Kinkead, Moshe Yair Levy

Future Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria

Nat Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Neil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M Larson, Susanne Saussele, Moshe Yair Levy

Br J Haematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Keith W Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W Burke

Haematologica· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke

Lancet Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Barry Paul, Michaela Liedtke, Jack Khouri, Robert Rifkin, Mitul D Gandhi, Moshe Y Levy

Future Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Paolo Strati, Morton Coleman, Rebecca Champion, Shuo Ma, Caterina Patti, Moshe Y Levy

Br J Haematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hamilton's rule in economic decision-making.
Moshe Levy, Andrew W Lo

Proc Natl Acad Sci U S A· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.
Moshe Levy, Lin Xie, Yuexi Wang, Frank Neumann, Shouryadeep Srivastava

Cancer Treat Res Commun· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Larysa Sanchez, Xavier Leleu, Jennifer L Beaumont, Hailin Yu, Stacie Hudgens, Moshe Levy

Am J Hematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospect theory, constant relative risk aversion, and the investment horizon.
Haim Levy, Moshe Levy

PLoS One· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Moshe Levy

Am J Hematol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Moshe Levy

BMC Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Holger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Moshe Levy

Am J Hematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Maria V Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W Auner, Xavier Leleu, Moshe Levy

J Hematol Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Moshe Levy

Lancet· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
Neil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah Larson, Susanne Saussele, Moshe Yair Levy

Leuk Lymphoma· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating the H Coupled Zn Transport Mechanism of ZIP4; Implications in Acrodermatitis Enteropathica.
Eitan Hoch, Moshe Levy, Michal Hershfinkel, Israel Sekler

Int J Mol Sci· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis